Clinical Studies
Breast Care
Cardiology
Colon Cancer
Dermatology
Diabetes
Gastrointestinal
HIV/AIDS
Mental Health
Neurology
Obesity/Weight Management
Women's Health
Other
Special Features
Advances/Research
| Principal Investigator: | Agustin Busta, MD | |
| Time frame of study: | 1 year | |
| Time frame of participation: | 16 months | |
| Number of participants needed: | Open | |
| Location of Study: | Fierman Hall 317E. 17TH St. 7th Floor New York, NY 10003 |
|
| Contact Research Coordinator | Amy Lam,
RN |
Summary:
The Division of Endocrinology and Metabolism at the Beth Israel
Medical Center is participating in a research project to assess the glycemic
control of Rimonabant in comparison with Glimeperide (Amaryl) over 1 year
in overweight/obese patients with type 2 diabetes not adequately controlled
with Metformin. IRB study #006-07. This is a double blind, parallel-group,
multicenter study.
Criteria for Participation:
• 18 years old or older
• Type 2 diabetes
• Taking metformin only
• BMI >27 kg/m2
• Willing to perform self monitoring blood glucose